Quratis Inc. (KOSDAQ:348080)

Market Cap	88.00B
Revenue (ttm)	2.28B +608.0%
Net Income	-24.09B
EPS	-370.46
Shares Out	81.79M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	159,514
Average Volume	256,108
Open	1,056.00
Previous Close	1,065.00
Day's Range	1,020.00 - 1,118.00
52-Week Range	516.00 - 2,095.00
Beta	-0.56
RSI	43.62
Earnings Date	n/a

About Quratis

Quratis Inc. engages in developing vaccines in South Korea. It is involved in developing QTP101, a vaccine for tuberculosis; QTP104, a next-generation mRNA vaccine; CPP (Cell Penetrating Peptide) Platform, a cell and bacterial penetration peptide drug delivery platform technology; and Peptide Nucleic Acid (PNA), a synthetic analogue of DNA in which the deoxyribose phosphate backbone. The company also offers drugs contract development and manufacturing services. Quratis Inc. was incorporated in 2016 and is based in Cheongju-si, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 348080

Financial Performance

In 2024, Quratis's revenue was 373.80 million, a decrease of -63.71% compared to the previous year's 1.03 billion. Losses were -26.27 billion, 54.6% more than in 2023.